Abstract: Method for manufacturing a mechatronic system comprising: a step of manufacturing a mechanical structure (SM) by three-dimensional printing by fused filament deposition of at least one first electrically insulating material (M1), and a step of manufacturing at least one electrical component (CE) in contact with at least one element of said mechanical structure and secured therewith; characterized in that said step of manufacturing at least one electrical component is implemented by three-dimensional printing by fused filament deposition of at least one second material (M2), conductive or resistive, directly in contact with said element of the mechanical structure. Apparatus for implementing such a method. Mechatronic system that can be manufactured by such a method.

Abstract: The present invention relates to methods and pharmaceutical compositions for expressing a polynucleotide of interest in the peripheral nervous system of a subject. In particular, the present invention relates to a method for selectively expressing a polynucleotide of interest in the peripheral nervous system of a subject in need thereof comprising the step of transducing a peripheral nerve of the subject with an amount of an AVV9 vector containing the polynucleotide of interest.

Abstract: The present invention is in the field of therapeutic drugs to treat leishmaniasis. In particular, the invention concerns adamantane and bicyclic monoterpenoid derivatives for use in the treatment of leishmaniasis.

Abstract: The present invention relates to the compounds of formula (I) below: wherein: X represents an oxygen atom, a sulfur atom, a nitrogen atom or a CH radical, The bond X—Y and Y are absent if X represents an oxygen or sulfur atom, the bond X—Y and Y are present if X represents a nitrogen atom or a CH radical, When present, Y represents a group R if X represents a nitrogen atom, a hydrogen atom or a group —NR1R2 if X represents a CH radical, (Het)Ar is an aromatic ring selected from the group consisting of aryl and heteroaryl groups, R3, R4, R5, R6 represent, independently of one another, a hydrogen atom, a halogen atom, a —NR12R13, a —SR14 group, a —OR14 group or a —CF3 group, When Y is —NR1R2, the groups —NR1R2 and (Het)Ar are in the cis-conformation, or a pharmaceutically acceptable salt thereof, for use in the treatment of proliferative diseases, infectious diseases, allergies, inflammation and/or asthma.

Abstract: A self-balancing scooter having a platform that includes a footstep, two wheels, and a gyroscopic stabilizing element that acts on wheel driving motors in such a way as to ensure that the self-balancing scooter is balanced and moves. The self-balancing scooter has a housing which accommodates a battery supplying power to the motors and is closed by a lid, the housing being removably accommodated on the platform of the self-balancing scooter such that the lid forms a footstep of the self-balancing scooter.

Abstract: The present invention relates to a method of selecting genetically modified hematopoietic stem cells using the combination of a positive selection marker and a MDR1 inhibitor.

Abstract: A subject of the present invention is a compound having the general formula (I): a pharmaceutically acceptable salt thereof or a tautomeric form thereof, wherein A, B3, B4, B5, Y, X, B1 and B2 are as defined in any one of claims 1 to 10. Another subject of the invention is the compound as defined above for use as a medicament, in particular for preventing and/or treating inflammation and inflammatory diseases, immune and auto-immune diseases, pain related diseases, genetic diseases and/or cancer.

Abstract: The present invention relates to mutated factor (FX) polypeptides and uses thereof for the treatment of haemophilia. In particular, the present invention relates to a mutated factor X (FX) polypeptide wherein the heavy chain comprises at least one mutation selected from the group consisting of: —the mutation which consists of the substitution of the glutamic acid residue (E) at position 255 of Seq. ID No. 1 by a glutamine residue (Q), an asparagine residue (N), a serine residue (S), an alanine residue (A), or a tyrosine residue (Y); —the mutation which consists of the substitution of the glutamic acid residue (E) at position 256 of Seq. ID No. 1 by a glutamine residue (Q); and —the mutation which consists of the substitution of the glutamic acid residue (E) at position 258 of Seq. ID No. 1 by a glutamine residue (Q).

Abstract: The present invention concerns an in vitro method for diagnosing a myeloid tumour or a lymphoid tumour in a subject, which comprises the step of analyzing a biological sample from said subject by (i) detecting the presence of a mutation in the Ten Eleven Translocation protein family member 2 gene (TET2) coding for the polypeptide having the sequence SEQ ID NO: 2, and/or (ii) analyzing the expression of the TET2 gene; wherein the detection of such a TET2 mutation, of the absence of expression of TET2 or of the expression of a truncated TET2 is indicative of a subject developing or predisposed to develop a myeloid tumour or a lymphoid tumour.

Abstract: The present invention concerns a method for labeling specifically living bacteria of a given category of bacteria in a sample comprising bacteria, the method comprising the steps of: a) incubating said bacteria of said sample with at least one analog of a monosaccharide compound, said monosaccharide being an endogenous monosaccharide residue of glycans of the outer membrane of such given category of bacteria, the said endogenous monosaccharide residue comprising an ulosonic acid or ulosonate salt residue, the said analog of a monosaccharide compound being a modified monosaccharide substituted at a given position by a first reactive chemical group capable to react with a second reactive group of a labeling molecule, the said given position being preferably a position which comprises a free group in the said endogenous monosaccharide residue incorporated within said glycans of the outer membrane of the bacteria, b) contacting said bacteria with a said labeling molecule comprising a said second reactive group

Abstract: The invention relates to compounds which are inhibitors of the polymerization of tubulin, to the methods for the production thereof, and to the uses of same.

Abstract: The invention relates to a distributed feedback laser diode (10) comprising a waveguide with a gain medium assisted by a network formed by a distribution of elements (22) including a sub-set comprising localised resonators (24) distributed along the axis of the waveguide, characterised in that the frequency characteristic of the feedback induced on the wave of the guide by the spatial distribution of said elements differs by less than 50% of the resonance frequency of said localised resonators.

Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.

Abstract: Disclosed is a compound of formula (Ia) for the use thereof in the treatment or prevention of diseases relating to the instability of mitochondrial DNA.

Abstract: Embodiments of the present disclosure relate to methods for ex vivo determining whether a patient with metastatic melanoma is likely to benefit from a treatment with an anti CTLA-4 molecule, preferably ipilimumab, by analyzing the gut microbiota in a fecal sample from said patient.

Abstract: A MRI device includes: structure applying a main magnetic field on an axis Z over a sample zone; structure emitting a magnetic field gradient and structure emitting a radiofrequency pulse, and a controller. The controller performs on the sample zone, a sequence including: a radiofrequency pulse and/or phase at each repetition; and a spatial gradient of the component along the Z axis. The controller is programmed so that, in the course of repeated applications of the pulse and of the gradient of the sequence of one and the same set: the radio frequency pulse follows, between its repeated applications, a periodic series for its amplitude and for a series U+t=v+i?v; and each repeated application of the gradient of magnetic field of the sequence a, according to a coding spatial direction, a non zero timing integral equal to A and identical for each application of gradient of this set.

Abstract: The present invention relates to an N-Methyl-D-aspartate (NMDA) receptor antagonist, for use in the treatment of diseases associated with angiogenesis such as tumor angiogenesis, ocular neovascular disease, Age-related macular degeneration (AMD).

Abstract: A kit for labeling bacteria, the kit including: an analog of an endogenous monosaccharide residue of glycans of the outer membrane of a given category of bacteria, the endogenous monosaccharide residue being an ulosonic acid or ulosonate salt residue, the analog of a monosaccharide compound being a modified monosaccharide substituted at a given position by a first reactive group capable of reacting with a second reactive group of a labeling molecule; the labeling molecule having the second reactive group capable of reacting with said first reactive group; reactants for generating the reaction of the first reactive group of the analog residue incorporated within the glycans of the outer membrane of the bacteria with the second reactive group of the labeling molecule; and a culture or incubation medium allowing growth of the given category of bacteria, specific to the growth of the given category of bacteria.

Abstract: This document provides methods and materials related to treating a disease. For example, this document provides methods for treating a subject's disease based on identifying the risk of progressive multifocal leukoencephalopathy PML using a genetic test.

Abstract: The present invention relates to the combination of a PARP inhibitor with a Dbait molecule for treating cancer.